roche

Roche's top-selling cancer-fighting drug Avastin has hit another roadblock in testing. In a Phase III study, Avastin failed to improve disease-free survival in early-stage colon cancer patients, the pharmaceutical giant reported.

Giant Swiss pharmaceutical company Roche has outlined a cost-cutting plan to help it offset pricing pressures in the U.S. and Europe, and following several setbacks in its late-stage research pipeline.

Swiss pharmaceutical giant Roche has struck a deal with Aileron Therapeutics worth up to $1.1 billion to gain access to a new class of drugs called stapled peptide therapeutics. This could yield new ways to attack hard-to-reach disease targets.

Roche's (RHHBY) blockbuster cancer drug, Avastin, is up for review by the U.S. Food and Drug Administration next month. If the FDA follows its advisory panel's recommendation from last month, it may revoke its approval of Avastin for the treatment of advanced breast cancer.

Pharmaceutical giant Roche said Friday that it would delay an FDA filing for its new diabetes drug for 12 to 18 months due to safety concerns. The beneficiary of Roche's misfortune is rival Amylin, which now jumps ahead in the race to get first approval of a once-weekly injectable type 2 diabetes drug.

Roche shares climbed nearly 2% Thursday after the Swiss drugmaker posted first-quarter sales that rose 6% to 12.2 billion Swiss francs ($11.61 billion), thanks to strong demand for key cancer drugs. The results beat the average sales forecast.

The U.S. diabetes drug market just got a little more competitive. Swiss drugmaker Roche (RHHBY) said Wednesday an experimental medicine in late-stage development works better in treating type 2 diabetes than Merck (MRK) Januvia, according to a clinical study.

Ever since China loosened its trade restrictions with the West, companies have jumped head-first into the Communist-run state, hoping to capitalize on selling products to the planet's most populous nation. Pharmaceutical companies have been no different, but at a somewhat more subdued rate because...

The male ego is a delicate thing. And when that ego finds its way into the upper ranks of a large company, it is uniquely vulnerable to the right sales pitch. As Fortune reports, last October one Dina Wein Reis (pictured), whose New York townhouse the FBI emptied of its millions in expensive...

Leave it to a skeptic like me to find something wrong with something that seems ao benevolent. Today, Swiss drug maker Roche Holdings AG (RHHVF) said it will cut the price of its viral drug Tamilflu for developing economies to what would amount to less than half the price it normally charges, and...